Introduction
The biology of vitamin D (VitD) is highly topical at present, with significant research being carried out in the contexts of cardiovascular, autoimmune and allergic conditions, chronic kidney disease (CKD) and cancer (1) . A recent systematic review of prospective observational studies showed that VitD deficiency (definitions of VitD status are given in Table 1 ) is a significant determinant of all-cause mortality in patients with CKD (2) . Renal transplant recipients (RTRs) have a high prevalence of VitD deficiency versus controls (3) . This arises for several reasons, including the mildto-moderate degree of renal functional impairment that characterizes most allografts (causing loss of renal tubular CYP27B1 [1-alpha-hydroxylase]), raised serum concentrations of fibroblast growth factor 23 (FGF-23) (4), immunosuppressive drugs inducing VitD catabolism (5) and medically advised sun-avoidance behavior (see below). FGF-23 actively inhibits VitD through suppression of CYP27B1, reducing 1-alpha-hydroxylation of 25-hydroxyvitamin D (25(OH)D) and induction of CYP24A1, which enhances calcitriol and 25(OH)D degradation (6) (Figure 1 ). The natural history of 25(OH)D and 1,25-dihydroxy-vitamin D (1,25(OH) 2 D 3 ) in incident RTRs has been reviewed elsewhere (7) ; while the skeletal, renal and gastro-intestinal effects of VitD on calcium and phosphate homeostasis are well known, with VitD deficiency linked to increased risk of postrenal transplantation (post-RTx) bone mineral loss and fractures (8) . VitD is also recognized to exert effects on both the innate and adaptive immune systems. In so doing, VitD status in RTRs can affect immunologically driven posttransplant outcomes, notably allograft rejection, transplant function and development of de novo posttransplant malignancies. This minireview examines the immunological effects of VitD that are of relevance to RTx and evaluates existing clinical evidence for VitD measurement and repletion in this cohort.
Immunological Effects of VitD Relevant to RTx (Figure 2)
The VitD receptor (VDR) is ubiquitously expressed in immune cells, including activated CD4 þ and CD8 þ T lymphocytes, and cells of the innate immune system, such as macrophages and dendritic cells (DCs). Immune cells not only express the VDR but may contain the machinery for producing biologically active 1,25(OH) 2 D 3 through inducible expression of the CYP27B1 (9) . These findings, along with strong epidemiological evidence linking VitD deficiency to multiple autoimmune diseases, suggest a physiological role for VitD in immune homeostasis. Experimentally, VitD metabolites, particularly 1,25 (OH) 2 D 3 , have multiple effects on immune system functioning, instructing both anti-microbial and immunoregulatory functions.
Immunoregulatory actions of VitD
VitD has clear effects on immune system functioning, characterized by inhibition of proliferation (10) , IL-2 (11) and interferon (IFN)-g production by CD4
þ T cells (12) and reduced cytotoxicity of CD8 þ T cells (13) . While VitD also enhances IL-4 production by CD4 þ T cells, its ability to enhance regulatory T cell (Treg) differentiation is particularly important. Not only does VitD induce differentiation of suppressive FOXP3
þ Tregs (14) , the most critical of immuno-Tregs for the prevention of autoimmune diseases in humans, but also IL-10-producing FOXP3 À type 1 Tregs (Tr1 cells) (15) as well as IL-10-producing B cells (16) . Although a definitive role for Tr1 cells or IL-10-producing B cells in transplant survival has not previously been described, FOXP3
þ Treg numbers infiltrating transplanted tissues do correlate, in general, with improved outcomes (17) .
The immunomodulatory effects of VitD are mediated both through direct effects on T cells and indirectly through modification of DC function (18) . DCs play a central role in the initiation, magnitude and quality of the adaptive immune response and modification of their function by VitD is clearly of relevance to transplantation as both passenger and recipient DCs are critical for induction of direct and indirect alloresponses, respectively (19) . VitD inhibits the maturation and antigen-presenting capacity of DCs and induces them to behave in a ''tolerogenic'' manner preferentially stimulating na€ ıve T cells both in vitro and in vivo (20) to mature into FOXP3 þ Tregs and Tr1 cells and enhancing the suppressive activity of these Tregs (21) . Inhibition of DCderived IL-12 production by VitD is also of great relevance as IL-12 is a central mediator in Th1 differentiation, a cell population intimately associated with transplant rejection.
VitD also regulates chemokine-chemokine receptor interactions, key steps in migration of inflammatory cells to sites of allograft rejection (22) . The CXCL10-CXCR3 axis is particularly important in transplant rejection, with levels of CXCL10 being associated with rejection in human transplant recipients (23) . CXCL10 is secreted by immune cells as well as resident cells of tissues and organs (23) and recruits multiple immune cells, including T cells, natural killer cells, macrophages and DCs through engagement of CXCR3. Thus, CXCL10 plays a role in the initiation and maintenance of Th1 alloresponses (24) . VitD decreases CXCL10 secretion by tubular epithelial cells, thus inhibiting immune cell infiltration of renal transplants and potentially protecting against allograft rejection (25) .
Anti-microbial actions
Monocyte activation with IFN-g or lipopolysaccharide results in up-regulation of both CYP27B1 as well as the VDR (26) . Autocrine engagement of the VDR results in production of natural anti-microbial peptides, such as cathelicidin and b-defensin 4 (27) , enhancing innate immune clearance of pathogen. Production of cathelicidin is further increased by the presence of pro-inflammatory IL-17, synergizing to remove inciting pathogens. Likewise, active (1,25(OH) 2 D 3 ) VitD can be stimulatory to other innate immune cells, such as monocytes and macrophages, promoting proliferation and secretion of highly inflammatory IL-1 (11) .
How can these immunological functions impact on transplant outcomes?
The balance between regulatory and inflammatory immune components is a key determinant of graft outcomes, resolution of chronic infections and responsiveness to neoantigens such as cancerous cells. From an immunological perspective, the dual functions of VitD (anti-microbial vs. immunoregulatory) appear counterintuitive; however, these functions are context-and time-dependent and carefully regulated, with the balance between the two in any given situation, dictating outcome. By modulating adaptive immune responses and down-regulating DC proliferation, maturation and antigen presentation capacity, VitD can ameliorate the risk of transplant rejection. Additional mechanisms, including regulation of chemokines responsible for leukocyte infiltration and down-regulating renal TGF-b1 production (which has pro-fibrotic activity), may also inhibit the evolution of rejection in RTx (28) . The ability of VitD to inhibit cell growth, promote apoptosis, alter cell adhesion and inhibit metastasis and angiogenesis is of 
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great relevance to the risk of cancer development in RTRs (see below), as is the ability of VitD to induce differentiation of immune inhibitory CD34 þ progenitor cells (observed in higher amounts in some cancers) (29) . These potential protective roles of VitD are supported by multiple empirical observations.
Experimental evidence from animal models shows that survival of allografts of bone marrow, heart, kidney, liver, pancreatic islets, skin and small intestine is significantly prolonged by administration of VitD and its analogues (30) , with increased resistance to opportunistic infections (31) , supporting the assertion that immunomodulation by VitD is a determining factor of outcomes. Additionally a small (nine donors and nine transplant recipients) prospective study in which donors received calcitriol therapy, which was then continued in the recipients, showed an expansion of CD4 þ CD25 þ Tregs in the calcitriol-treated group (32). Another small prospective study treating 24 transplant recipients with calcitriol observed decreased costimulatory molecule expression (HLA-DR, CD28, CD86 and CD40) on white blood cells. Together these studies provide evidence of the immunomodulatory properties of VitD receptor agonists (VDRAs-active VitD compounds, such as calcitriol and paricalcitol) after transplantation. VDRAs could thus be used as potentially immunomodulatory agents in RTx. Calcitriol analogues, such as paricalcitol, which could exert immunomodulatory activity with a lower risk of causing hypercalcemia, have been developed for clinical use for secondary hyperparathyroidism (33, 34) .
VitD Repletion Studies in RTx
Given plausible biological links between VitD and the pathophysiology of diseases endemic in the RTR population, the clinical evidence for VitD repletion in RTRs is reviewed here, excluding those predominantly focusing on skeletal outcomes, which are reviewed elsewhere (35) . It should be noted that important clinical safety data for VitD repletion can be found in three separate comprehensive Cochrane reviews of bone disease in nondialysis, dialysis and RTx (8, 36) where adverse effects of VitD repletion were described only in the minority of studies (4/16 studies in CKD, 8/60 studies of dialysis and 0/23 studies in RTx) suggesting it is generally a well-tolerated and safe therapy. However, higher repletion doses than those used in these studies are needed to bring serum levels significantly above 30 ng/mL (75 nmol/L).
VitD and allograft outcomes (Table 2 ) Given the immunomodulatory effects of VitD, it has been hypothesized that reduced serum 25(OH)D concentrations are associated with poorer graft outcomes. Reduced serum 25(OH)D concentrations in RTRs is commonplace (37) . Three out of four observational studies published to date draw a direct link between VitD levels and allograft outcomes (summarized in Table 2 ). Notably, in an observational study of 90 Polish RTRs, 25(OH)D deficiency at time of transplantation was significantly associated with delayed graft functioning and an increased risk of acute rejection episodes over a 2-year follow-up period (38) . This would be clinically highly significant as both of these are known risk factors for graft fibrosis and impaired allograft function. The other two observational studies showed an association between 25(OH)D levels at time of transplantation and renal function over a 2-to 4-year follow-up period (39, 40) . The more recent study of 634 patients (40) , demonstrated an association between low serum 25(OH)D at 3 months posttransplantation and increased risk of interstitial fibrosis/tubular atrophy on 12-month transplant biopsies at, but not with mortality. The fourth observational study is not directly comparable to the first three as it was carried out in a pediatric cohort with stable graft function some time (mean AE SD 4.9 AE 0.5 years) after transplantation (41) . Given the low event rate (only 6 patients out of 64 had a decrease in GFR of !50% and there were only 14 acute rejection episodes), this was an underpowered study to determine the effects of VitD on long-term transplant function.
Interventional studies of VitD supplementation in the context of RTx have also yielded conflicting data, most likely attributable to difference in patient selection, control group selection, time since transplantation, VitD repletion regimen and formulation of VitD. These caveats mean that it is difficult to directly compare study cohorts and formulate an ideal repletion strategy. While supplementation posttransplant with calcitriol was associated in three studies with either reduced numbers of acute rejection episodes (42, 43) , better transplant function (44) and improved graft survival (43) a smaller interventional study, using cholecalciferol in the first year posttransplantation, gave conflicting results (45) . There are significant difficulties in conducting clinical VitD research, which are elaborated below, but these trials can be individually critiqued. The data set of Tanaci et al (42) is a retrospective small series with baseline imbalances between osteoporotic and nonosteoporotic cohorts; the study of
Ozdemir et al (44) does not disclose the calcitriol dosing regime and has a surprisingly high late rejection rate in the control group while Courbebaisse et al (45) was not a randomized prospective study and the repletion strategy only achieved a mean 25(OH)D concentration of 31.8 AE 7.1 ng/mL, arguably below the nephroprotective threshold. Some of the discrepancy between studies may also be explained by the lack of a contemporary control population in the latter study.
In conclusion, there is an association between serum VitD concentrations and allograft outcomes; however, the evidence for causality has yet to be tested in an RCT.
VitD and cancer (Table 3 ) RTRs are at a three-to fivefold increased risk of developing malignancies compared to the general population and an inverse correlation between general population serum 25(OH)D concentrations and the risk of solid organ malignancies (especially breast and colorectal cancer) is observed epidemiologically (46) . Limited observational epidemiological data exist analyzing VitD status and de novo malignancies in RTRs (47, 48) . The shorter of the two studies (47), with a 3-year follow-up period, describes a significant increase in malignancy risk with VitD deficiency, with a hazard ratio of 1.12 for every 1 ng/mL decline in 25(OH)D 3 . However, a longer follow-up study with the same number of patients found no association over a 10-year follow-up period between VitD levels and risk of de novo malignancy (48) . Further work is needed to establish whether these results can be explained by risk segregation with cancer type, particularly viral-related cancers. A single interventional Eight patients in the treatment arm were excluded from analysis due to noncompliance (Continued) repletion study exists in the literature (49) describing a decreased posttransplantation malignancy risk associated with VDRA supplementation (calcitriol and alfacalcidol). This study needs to be assessed with the caveat that the overall ''event rate'' was exceedingly small (2.1 and 3.5 de novo malignancies per 100 patient years in VitD-treated and -untreated subjects, respectively).
Due to the increased risk of skin malignancies with immunosuppression (particularly squamous cell carcinomas), there has been long-standing advice to RTRs to avoid solar UV exposure. In RTRs, regular application of SPF-50 sunscreen is associated with fewer skin lesions over a 2-year period, but also a lower mean concentration of 25(OH) D levels (mean value 53 ng/mL vs. 60 ng/mL) (50). Higher levels of VitD are similarly associated with an increased risk of cancer, explained by greater UV exposure conferring increased disease risk (51) . These data demonstrate the difficulties of drawing conclusions using only epidemiological studies. 
Other Key Effects of VitD in RTRs
VitD status contributes significantly to skeletal health. A Cochrane review (8) in 2007 concluded that from 24 trials (1299 patients) no individual intervention (bisphosphonates, VitD sterol or calcitonin) was associated with reduced fracture risk in RTRs compared with placebo, but by combining results for all active interventions against placebo it could be demonstrated that any treatment of bone disease was associated with reduced risk of fracture (relative risk 0.51, 95% confidence interval 0.27-0.99). Bisphosphonates (any route), VitD sterol and calcitonin all increased lumbar spine bone mineral density. Bisphosphonates and VitD also had a beneficial effect on the bone mineral density at the femoral neck. This represents the ''classical'' VitD therapeutic paradigm and is reviewed in depth elsewhere (35) .
Cardiovascular disease (CVD) is the most common cause of death in RTRs, with chronic inflammation a key etiological factor. As well as epidemiological data showing a link between low serum VitD concentrations and predisposition to cardiovascular events, meta-analyses have shown that oral VitD treatment contributes to improved all-cause mortality through an associated reduction of deaths from cardiovascular events (52) . However, a recent systematic analysis showed that the quality of current trial data is inadequate to draw conclusions about the relationship between VitD status and mortality from CVD in the general population (53) . Further discussion of the role of VitD in CVD is beyond the scope of this review but has been reviewed elsewhere (54) .
Issues in VitD Research
There are several caveats that cloud the interpretation of clinical VitD research data. First, reliably assessing VitD status and activity is itself a challenge (55 Third, the species and route of administration of VitD treatment used in interventional studies are confounding. There are six to eight different possible forms of ViD, including ergocalciferol, cholecalciferol, calcidiol, calcitriol, 1-alfacalcidol and paricalcitol, with almost no head-to-head studies comparing them in RTRs. These have different affinities for the VDR, potencies, biological activities and side-effect profiles-for a detailed discussion see (59) . VitD can raise serum creatinine, due to either an effect on the renin-angiotensin-aldosterone system or direct alteration in tubular handling of creatinine (60) . Further variables include the route (oral, intramuscular and intravenous-the latter confers greater bioavailability) and frequency of administration, whether daily, weekly or monthly (61).
Fourth, although there is a high prevalence of VitD insufficiency in transplantation, there is no consensus dosing strategy for VitD repletion. One study showed that 100 000 IU of cholecalciferol fortnightly for 2 months (equivalent to 6600 IU/day) corrected 25(OH)D insufficiency in RTRs and significantly decreased serum parathyroid hormone (PTH) concentrations without side-effects. This study also highlighted that 100 000 IU of cholecalciferol every other month from months 6 to 12 posttransplant (the ''maintenance period'') was insufficient to maintain serum 25(OH)D levels above 30 ng/mL in about half of the patients studied, consistent with a previous report (62) . The authors pharmacokinetically simulated an optimal dosing regimen to maintain 25(OH)D concentrations between 30 and 80 ng/mL (100 000 IU six times fortnightly, then 100 000 IU monthly until the end of the first year) (63) , but this proposal remains to be tested prospectively.
Fifth, and most importantly, the optimum marker denoting biological VitD repletion has yet to be determined. Although biochemical markers (principally PTH and alkaline phosphatase) have traditionally been used to monitor repletion, the reliability and clinical relevance of PTH levels to infer changes in 25(OH)D levels in RTRs have been called into question. In a cohort study of 419 RTRs, 25(OH)D, estimated GFR and serum phosphate combined only accounted for 19% of the variance in PTH levels, indicating that VitD supplementation alone is likely to have only a limited effect on PTH levels (64) . Bone mineral density, graft and patient survival are all relevant, additional, parameters/biomarkers for consideration.
Future Directions-Upcoming Trials
Although tentative associations have been made between VitD repletion and improvement of clinical outcomes in RTRs, this review highlights several deficiencies in our current knowledge that need to be addressed. Table 4 lists three actively recruiting VitD repletion trials, evaluating a range of primary end points. Encouragingly, there is focus on allograft function, cardiovascular outcomes and de novo malignancy.
The VITA-D trial (65) is a randomized, placebo-controlled double-blind study of 200 transplant recipients with followup duration of 1 year, with entry criteria being 25(OH)D serum concentration of <50 nmol/L. Incidence of acute rejection episodes, number and severity of infections (as measured by C-reactive protein) and GFR will be monitored. VITA-D is primarily aimed at evaluating short-term outcomes as only newly transplanted patients are being recruited and will be the first trial to report on VitD supplementation in de novo RTRs. The VITALE trial (66) will evaluate the differential effect of low-and high-dose cholecalciferol supplementation. Six hundred forty patients ranging from 12 to 48 months posttransplantation will be recruited to capture medium-term outcomes, particularly the development of new cancers and CVD. Although better powered than VITA-D, follow-up is still short at 24 months, in comparison with epidemiological literature in general. CANDLE-KIT (67) will recruit 246 RTRs, of at least 1 year posttransplantation, and randomize them to receive no additional treatment or combinations of cholecalciferol and an erythropoiesis-stimulating agent. Transplant function over a 2-year follow-up period will be the primary outcome measure of this trial. Interestingly, entry criteria for this trial do not include baseline VitD insufficiency/ deficiency.
Conclusion
Research concerning the benefits of VitD supplementation in RTRs is clearly still evolving. While there is consistent epidemiological evidence suggesting an association between replete VitD status and improved clinical outcomes in RTRs, particularly skeletal outcomes (bone mineral density and fractures), we lack compelling evidence at the moment that measurement and repletion of VitD are mandatory for RTRs. The KDIGO guidelines recommend the use of VitD in RTRs for the prevention and treatment of transplant bone disease (68) , but as yet a hard case for VitD repletion to optimize immunomodulation in RTRs has not been made. Given recent developments in our understanding of its molecular properties, VitD probably has a multifaceted role, which cannot be fully appreciated by examining hard clinical end points such as mortality alone. Future work is urgently needed to translate molecular biology into clinical outcomes. Phase 4 open-label trial VitD supplementation and anemia correction (with Mircera 1 ) over 2-year follow-up. 246 patients will be recruited who are at least 12 months posttransplant, with eGFR ranging from 15 to 60 mL/min. Inclusion criteria will not include VitD levels but patients must have Hb <10.5 g/dL without iron deficiency. They will be randomized to low Hb (!9.5 and <10.5 g/ dL) with no VitD, low Hb (!9.5 and <10.5 g/dL) with VitD (1000 IU/day), high Hb (!12.5 and <13.5 g/dL) without VitD or high Hb (!12.5 and <13.5 g/dL) with VitD (1000 IU/day). Outcomes will be followed up for 2 years Disclosure
